Selective ROCK2 Inhibitors for Viral Sequelae and Cytokine Storm
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections, particularly coronavirus infections, are limited to symptom alleviation and there is a need for therapies that can effectively treat and prevent sequelae resulting from these infections, including conditions such as inflammation, fibrosis, and cytokine storm.
Innovation Solution
The use of Rho-associated coiled-coil kinase 2 (ROCK2) inhibitors, including compounds like antisense RNA, siRNA, and miRNA, to interfere with viral pathways and secondary conditions caused by viral infections, such as inflammation and fibrosis, providing potent antiviral effects and treatment for sequelae like long COVID.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for viral infections are used, then symptom alleviation is achieved, but effective treatment and prevention of sequelae such as inflammation, fibrosis, and cytokine storm is not available
Solution Approach 1:
The ROCK2 inhibitor is designed to perform multiple therapeutic functions simultaneously: it directly inhibits viral replication, reduces inflammation, prevents fibrosis, and mitigates cytokine storm. This multi-functional approach allows a single agent to address both the primary viral infection and its secondary sequelae, thereby improving treatment reliability and versatility.
2Reliability
If ROCK2 inhibitors are used to treat viral infections, then antiviral activity and reduction of sequelae is achieved, but potential off-target effects on ROCK1 and other pathways may occur
Solution Approach 1:
The inhibitor is engineered with specific molecular characteristics that enable it to selectively bind to ROCK2 while minimizing interaction with ROCK1 and other related kinases. This selective binding profile is achieved through optimized structural features that match the unique active site geometry of ROCK2, thereby maintaining high antiviral efficacy while reducing off-target effects.
3Adaptability or versatility
If ROCK2 inhibition is used to treat inflammation and fibrosis, then secondary conditions are alleviated, but the complexity of the treatment mechanism increases
Solution Approach 1:
The ROCK2 inhibitor acts as a molecular intermediary that blocks the downstream signaling pathways common to multiple pathological processes. By inhibiting ROCK2, it interrupts the signaling cascade that leads to inflammation, fibrosis, and cytokine storm, thereby treating multiple secondary conditions through a single mechanistic pathway rather than requiring multiple separate interventions.
Data Source
AI summary
The disclosure provides compositions and methods comprising selective inhibitors of Rho-associated coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coronavirus infections such as SARS-CoV-2, and in the treatment of sequelae resulting from the viral infection, including sequelae resulting from coronavirus infection.